• Users Online: 352
  • Print this page
  • Email this page

Table of Contents
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 196-197

Relatlimab and nivolumab in untreated advanced melanoma

Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Date of Submission04-Feb-2022
Date of Decision26-Feb-2022
Date of Acceptance01-Mar-2022
Date of Web Publication31-Mar-2022

Correspondence Address:
Ajay Gogia
Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/crst.crst_71_22

Rights and Permissions

How to cite this article:
Ganguly S, Gogia A. Relatlimab and nivolumab in untreated advanced melanoma. Cancer Res Stat Treat 2022;5:196-7

How to cite this URL:
Ganguly S, Gogia A. Relatlimab and nivolumab in untreated advanced melanoma. Cancer Res Stat Treat [serial online] 2022 [cited 2022 May 21];5:196-7. Available from: https://www.crstonline.com/text.asp?2022/5/1/196/342448

Tawbi et al.[1] recently reported improvement in progression-free survival (PFS) with the relatlimab–nivolumab combination over nivolumab monotherapy in previously untreated, unresectable/metastatic melanoma. The nivolumab–ipilimumab combination has improved the response rate in advanced melanoma with a significant increase in grade 3/4 adverse events (55%),[2] making its real-world application difficult. Hence, the incidence of grade 3/4 adverse events with the relatlimab–nivolumab combination (18.9%) appears encouraging. Nevertheless, 30.4% (108/355) patients discontinued the combination treatment due to reasons other than disease progression. Hence, predictive models or biomarkers for appropriate patient selection are crucial to explore.

For BRAF-mutant melanoma, combination therapy with BRAF/MEK inhibitors is an acceptable first-line strategy.[3] Among 38.5% (275/714) patients positive for BRAF mutations, subsequent systemic therapy with BRAF/MEK inhibitors could be started in only 19.3% (91/470) after discontinuing study treatment. Combination of programmed cell death protein 1 blockade with BRAF/MEK inhibition has also been explored in advanced melanoma with improved survival outcome.[4] With preclinical evidence suggesting proimmunogenic effect of MEK inhibition,[5] it is important to investigate the combination of LAG3 blockade with BRAF/MEK inhibition in advanced BRAF-mutant melanoma.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 2022;386:24-34.  Back to cited text no. 1
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.  Back to cited text no. 2
Mittal A, Gupta A, Rastogi S. Melanoma at American Society of Clinical Oncology 2020-An update and its implications in the Indian setting. Cancer Res Stat Treat 2020;3:594-7.  Back to cited text no. 3
  [Full text]  
Liu Y, Zhang X, Wang G, Cui X. Triple combination therapy with PD-1/PD-L1, BRAF, and MEK inhibitor for stage III–IV melanoma: A systematic review and meta-analysis. Front Oncol 2021;11:693655.  Back to cited text no. 4
Baumann D, Hägele T, Mochayedi J, Drebant J, Vent C, Blobner S, et al. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nat Commun 2020;11:2176.  Back to cited text no. 5


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal